Catalent Has Acquired MaSTherCell
The acquisition positions Catalent as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics
Catalent has acquired MaSTherCell, a technology-focused cell and gene therapy development and manufacturing partner for leading cell therapy innovators.
MaSTherCell provides Catalent with advanced technology and capabilities in cell therapy development and manufacturing to create a comprehensive solution for advanced biotherapeutics. In combination with Catalent’s deep experience in viral vector scale-up and production, MaSTherCell’s expertise in both autologous and allogeneic development and manufacturing allows Catalent to be a full-service partner for CAR-T immunotherapies and beyond.
MaSTherCell’s unique and comprehensive cell therapy offering includes a wide-range of expertise across a variety of cell types including, MSCs, tumor infiltrating leukocytes (TILs), natural killer cells (NKs), iPSCs, and chimeric antigen receptor T cells (CAR-T).
MaSTherCell’s capabilities include:
- Process and analytical development
- Pilot runs
- Engineering runs
- Clinical readiness
- Agile CGMP clinical and commercial manufacturing
- In-house QC testing
With facilities in both the US and Europe, MaSTherCell has global expertise to enable success for a large customer base. MaSTherCell’s development facility in Gosselies, Belgium offers autologous and allogeneic clinical cell therapy manufacturing with an additional large-scale clinical and commercial manufacturing space under construction and expected to be fully commissioned in 2021. Additionally, MaSTherCell has just completed a new state-of-the-art clinical facility in Houston, Texas that is expected to be fully validated in Q2 2020, with preliminary planning underway for future expansions.
Catalent will leverage its expertise in build-outs, scale-ups and commercial manufacturing as well as its resources to support MaSTherCell’s continued expansion in order to best support Catalent’s customers and their patients.
Catalent’s Comprehensive Biologics Platform
MaSTherCell’s cell and gene therapy services are a strong complement to our broad biologics offering including: